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Methadone maintenance therapy is the standard of care in many countries for opioid-
dependent women who become pregnant. Despite recent evidence showing significant
neurodevelopmental changes in children and adults exposed to both licit and illicit sub-
stances in utero, data on the effects of opioids in particular remains scarce.The purpose of
this study was to examine the effects of opiate use, in particular methadone, on various fetal
cortical and biometric growth parameters in utero using ultrasound measurements done
at 18–22 weeks gestation. Head circumference (HC), bi-parietal diameter, lateral ventricle
diameter, transcerebellar diameter, thalamic diameter, cisterna magna diameter, and femur
length were compared between fetuses born to methadone-maintained mothers and non-
substance using controls. A significantly larger thalamic diameter (0.05 cm, p=0.01) was
observed in the opiate-exposed group. Thalamic diameter/HC ratio was also significantly
raised (0.03 mm, p=0.01). We hypothesize here that the increase in thalamic diameter
in opiate-exposed fetuses could potentially be explained by regional differences in opioid
and serotonin receptor densities, an alteration in monoamine neurotransmitter systems,
and an enhancement of the normal growth increase that occurs in the thalamus during
mid-gestation.
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INTRODUCTION
Methadone maintenance therapy is the standard of care in many
countries for opioid-dependent women who become pregnant (1,
2). Although there are many benefits to the use of methadone
during pregnancy, it readily crosses the placenta, enters the blood-
stream of the fetus and imposes potential risks (3, 4). The main
documented adverse outcome of methadone use during preg-
nancy is the development of neonatal abstinence syndrome (NAS),
with withdrawal being reported in more than 50% of infants born
to methadone-maintained mothers (5). Opiate-exposed neonates
have also been reported to be born prematurely and have lower
birth weights, lengths, and head circumferences (HC) up to 5 years
of age (6–8). Recent evidence shows that exposure to both licit
and illicit substances causes significant structural brain changes
in children, adolescents, and adults, which leads to the hypothe-
sis that there may be significant effects on the brains of fetuses
as well (9–11). These changes are diverse not only in terms of
regions of the brain affected, but also in terms of the specific
effects themselves, and occur on a cellular, macroscopic structural,
and functional/behavioral level (9–13).
The size of a multitude of cortical and sub-cortical structures,
the integrity of white matter tracts, changes in blood-flow pattern,
and alterations in neurotransmitter levels have all been shown to
be affected by different substances (9, 11, 12, 14). However, the
data on the specific effects of opiates (methadone in particular)
is scarce and only a few studies on their effects on brain devel-
opment in humans can be identified (11, 15). One such study
showed a reduction in the volumes of structures including the
cerebral cortex, amygdala, and basal ganglia in children exposed
primarily to heroin in utero (11). In an older study conducted
with ultrasound, the thalamic cross-sectional area and HC were
found to be larger in methadone-exposed infants at 6 months of
age when compared to controls (15). Interestingly, in the rat opi-
oids appear to selectively accumulate in the nervous tissues of fetal
and pre-weaning rats, perhaps due to an increased permeability
of their blood–brain barriers (16–18). Furthermore, research has
shown that the limbic system, thalamus, and striatum appear to
have among the highest concentration of opioid receptors (18),
and therefore, it would seem likely that in utero opioid exposure
would have the most significant effect in those areas. The stud-
ies mentioned above (11, 15) show some support for this notion,
however, further evidence is needed. No evidence can be found
specifically on the effect of opioid exposure in the human brain
prenatally. Therefore, the purpose of this study was to examine the
effects of opiate use, in particular methadone, on various fetal cor-
tical and biometric growth parameters in utero using ultrasound
measurements done at 18–22 weeks gestation. Use of such non-
invasive and readily available measures could potentially allow for
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easier identification of the neurodevelopmental effects of opioid
use during pregnancy.
MATERIALS AND METHODS
SUBJECTS
A retrospective medical record review was conducted on fetuses
born to methadone-maintained pregnant women at a tertiary
birthing unit between 2000 and 2006 inclusive. Women who had
undergone their fetal anomaly scans (FAS) between gestational
ages 18 and 22 weeks were included in our cohort. One hundred
and eight control subjects who did not use illicit drugs or alco-
hol were identified from the local obstetric database and matched
to our subjects based on maternal age, gender of the fetus, gesta-
tional age at FAS± 5 days, and birth month± 2 months. Exclusion
criteria for both our subjects and controls included women with
preeclampsia, hypertension, diabetes mellitus, multiple pregnan-
cies, fetuses with congenital malformations, or non-satisfactory
scans (that is unable to identify or measure required parameters).
This study was approved by the Human Research Ethics Commit-
tees of both the Nepean Blue Mountains Local Health District and
the University of Sydney.
PARAMETERS MEASURED
Images were captured on the ultrasound machines GE Voluson
730 (GE Medical Systems, Piscataway, NJ, USA), GE Voluson i
(GE Medical Systems, Piscataway, NJ, USA), or Medison Accuvix
V20 Prestige (Samsung Medison, Seoul, South Korea). The mea-
surements used for our data were taken by accredited perinatal
sonographers. These included bi-parietal diameter (BPD), HC,
femur length (FL), transcerebellar diameter (TCD), and lateral
ventricle diameter. Additionally, thalamic diameter and cisterna
magna diameter were measured using Adobe Photoshop v.7.0
(Adobe Systems Inc., USA). Gestational age of the fetus was based
on last menstrual period (LMP) and confirmed by an ultrasound
performed before 20 weeks gestation.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS v.21.0 (SPSS Inc.,
Chicago, IL, USA). Descriptive statistics are reported as means
and standard deviations. The data was confirmed to be normally
distributed and variables were compared between the opiate-
dependent group and the control group using independent sam-
ples t -tests. Adjusted analysis was undertaken using multiple
regression modeling. A two tailed p-value of<0.05 was considered
statistically significant.
RESULTS
Forty-two fetuses with FAS between 18 and 22 weeks were iden-
tified from our cohort of methadone-maintained mothers. The
exact amount of opiate and other illicit drug use during preg-
nancy is intrinsically difficult to identify and is mainly dependent
on self-reporting. However, our subjects were primarily opiate-
dependent and ultimately maintained on methadone substitution
therapy during their pregnancy. Although alcohol use was not con-
sidered an exclusion criterion, only 1 of 42 subjects reported using
alcohol. Further details of this cohort are described in previous
publications (19, 20) and other pertinent maternal and neonatal
demographic characteristics are shown in Table 1.
Table 1 | Maternal and neonatal characteristics.
Opiate-exposed
group, n=42
Control group,
n=108
Maternal characteristics
Age (years) 27.4±4.3 27.4±4.3
Smokers 39 (93%) 15 (14%)
Alcohol use 1 (2%) 0 (0%)
Neonatal characteristics
Gender 20 female (48%),
22 male (52%)
53 female (49%),
55 male (51%)
Gestational age at FAS
(weeks+days)
19+3±5 days 19+3±5 days
NAS treated with morphine 36 (86%) 0 (0%)
Urine drug screen at birth 37 (88%) 0 (0%)
Substances reported in UDS
Methadone 35 (94%)
Opiates 6 (16%)
Benzodiazepines 4 (11%)
Cannabis 10 (27%)
Amphetamines 1 (3%)
NAS, neonatal abstinence syndrome; UDS, urinary drug screen; FAS, fetal
anomaly scan.
All parameters measured during the FAS were compared
between the opiate – exposed group and the control group
(Table 2). Of these, there were no statistically significant differ-
ences observed between the groups except for thalamic diameter.
The diameter of the thalamus was, on average, 0.05 cm larger
in the opiate-exposed group compared to the control group
(p= 0.01). Adjusted for gestational age, the thalamic diame-
ter was still significantly larger by 0.05 cm (95% CI: 0.10–0.85,
p= 0.01) in the exposure group. The ratio of thalamic diame-
ter/HC was also compared between the two groups and found
to be significantly larger in the opiate-exposed group (0.90± 0.1
versus 0.87± 0.1 mm; p= 0.01). Finally, because of the known
effect that cigarette smoking has on growth in the developing
fetus (9, 19), comparisons of all parameters measured during
the FAS between smokers and non-smokers were also performed
(Table 3).
There was no statistically significant difference in any of
the variables except thalamic diameter. The thalamus was, on
average, 0.04 cm larger in the smoking group compared to
the non-smoking group (p= 0.02). When comparing the thal-
amic diameter/HC ratio in the smokers versus non-smokers,
the ratio was found to be significantly larger in the smoking
group (0.90± 0.07 mm in smokers versus 0.86± 0.07 mm in non-
smokers; p= 0.01). Smoking could not be controlled for in our
patient and control group selection. As such, smoking was almost
completely confounded by methadone use and it was not possible
to model an interaction in this patient population. Table 4 provides
a descriptive analysis, however, showing a trend toward a larger
thalamic diameter with exposure to either cigarette smoking or
opiate-exposure independently, with a possible cumulative effect
of exposure to both.
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Table 2 | Comparison of FAS measurements between opiate – exposed fetuses and controls.
Variable Controls, n=108
(cm±SD)
Opiate-exposed, n=42
(cm±SD)
Difference (control-methadone)
and 95% CI
p-Value
Bi-parietal diameter 4.44 (0.26) 4.43 (0.27) 0.01 (−0.08 to 0.11) 0.78
Head circumference 16.54 (0.96) 16.55 (1.04) −0.01 (−0.36 to 0.34) 0.94
Lateral ventricle diameter 0.77 (0.13) 0.74 (0.09) 0.03 (−0.01 to 0.07) 0.19
Cerebellar diameter 1.9 (0.15) 1.92 (0.12) −0.02 (−0.07 to 0.03) 0.46
Thalamus diameter 1.43 (0.10) 1.48 (0.10) −0.05 (−0.09 to −0.01) 0.01
Cisterna magna diameter 0.40 (0.08) 0.42 (0.08) −0.02 (−0.04 to 0.01) 0.32
Femur length 3.02 (0.24) 3.01 (0.28) 0 (−0.08 to 0.10) 0.85
Bold font indicates significant difference.
Table 3 | Comparison of FAS measurements between smokers and non-smokers.
Variable Non-smokers, n=96
(cm±SD)
Smokers, n=54
(cm±SD)
Difference (non-smokers – smokers)
and 95% CI
p-Value
Bi-parietal diameter 4.45 (0.26) 4.43 (0.28) 0.02 (−0.07 to 0.11) 0.65
Head circumference 16.55 (0.92) 16.52 (1.08) 0.04 (−0.29 to 0.36) 0.83
Lateral ventricle diameter 0.76 (0.07) 0.76 (0.18) 0.00 (−0.04 to 0.04) 0.90
Cerebellar diameter 1.92 (0.11) 1.90 (0.19) 0.02 (−0.03 to 0.06) 0.49
Thalamus diameter 1.43 (0.10) 1.48 (0.10) −0.04 (−0.08 to −0.01) 0.02
Cisterna magna diameter 0.40 (0.08) 0.41 (0.08) −0.01 (−0.04 to 0.02) 0.53
Femur length 3.02 (0.23) 3.02 (0.29) 0 (−0.09 to 0.08) 0.89
Bold font indicates significant difference.
Table 4 | Descriptive analysis of thalamic diameter in four exposure
groups: non-smoking controls, non-smoking opiate-exposed,
smoking controls, and smoking opiate-exposed.
Group Thalamus size (cm)
Mean±SD
95% CI
Non-smoking controls (n=93) 1.43±0.01 1.41–1.45
Non-smoking opiate-exposed (n=3) 1.46±0.05 1.35–1.56
Smoking controls (n=15) 1.45±0.03 1.39–1.50
Smoking opiate-exposed (n=39) 1.48±0.17 1.45–1.52
DISCUSSION
An analysis of several parameters measured during the FAS of
opiate-exposed and control fetuses have demonstrated a signifi-
cant increase in the thalamic diameter in opiate-exposed fetuses.
The thalamic diameter/HC ratio was also significantly increased in
the opiate-exposed group, indicating that the thalamus grew out of
proportion with the rest of the head. This result was unexpected,
and is difficult to explain due to limited literature on the topic.
Only one previous study has looked specifically at thalamic size
in neonates born to methadone-maintained mothers (15). This
study used ultrasound to demonstrate that thalamic area was not
significantly different at birth and at 1 month (though trended
toward being smaller) when compared to controls. Between 1 and
6 months of age, however, the growth rate of the thalamus more
than doubled that of the controls, resulting in significantly larger
thalami at 6 months. Other neuroimaging studies using MRI have
shown a decrease in thalamic volume after pre-natal exposure to
alcohol (21), methamphetamine (22), and cocaine (9). However,
these studies have all been performed on children and adolescents
years after exposure to such substances. The pre-natal increase in
thalamic size, we have demonstrated may potentially be explained
by normal developmental patterns of the thalamus and also by
regional differences in opiate-receptor density and monoamine
neurotransmitter systems within the brain.
Overall, very little is known about the normal pre-natal devel-
opment of the thalami. Both a recent 3D ultrasound report (23)
and an older histochemical study (24), however, have demon-
strated that growth of the thalamus does not progress linearly
in humans, and that there is a striking increase in size from 20
to 28 weeks gestation, with slower growth both before and after
that time. Interestingly, the thalamus has also been shown to have
one of the highest concentrations of opioid receptors in the brain
overall, with the density of those receptors increasing with gesta-
tional age and into adulthood (18, 25). Furthermore, the thalamus
is reported to have one of the highest concentrations of serotonin
transporters in the brain (26), and methadone exposure has been
shown to increase the concentration of the serotonin metabolite
5-hydroxyindoleacetic acid (5-HIAA) particularly in the striatum,
an area of the brain intimately connected to the thalamus (27).
This is interesting, as many of the proposed neurodevelopmental
effects of other substances such as methamphetamine,cocaine,and
tobacco are attributed to alterations in monoamine neurotrans-
mitter systems and these neurotransmitters reportedly play a key
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trophic role in brain development, particularly in the development
of the thalamus (9, 28, 29). Therefore, our proposed hypothesis is
that pre-natal opiate-exposure alters monoamine neurotransmit-
ter systems and somehow “ramps-up” the normal developmental
increase in thalamus size that occurs around mid-gestation; the
thalamus being particularly susceptible due to the increased den-
sity of both opioid and serotonin receptors. The actual functional
implications of such a change in thalamic size are unknown. How-
ever, as the thalamus is responsible for an array of critical functions
such as relaying information between cortical areas and transmit-
ting peripheral stimuli to the cortex (23), the changes we have
demonstrated may well prove to be clinically significant.
Briefly, although it is difficult in this case to disentangle the
effects of opiates versus cigarette smoking on the size of the thala-
mus in our subjects, it appears that nicotine may be independently
causing an increase in thalamus size as well. If this is the case,
it could potentially be due to nicotine’s ability to bind nicotinic
acetylcholine receptors (nAChRs) and the fact that acetylcholine
(ACh) plays a vital role in brain development and maturation. By
binding nAChRs, nicotine has the ability to disrupt brain devel-
opment and potentially alter the size of distinct brain regions (30,
31). Furthermore, nicotine, like methadone, alters monoamine
systems and also has the potential to affect thalamic size in this
manner (32). More research needs to be done however, specifically
examining the effects of cigarette smoking on neurodevelopment.
Limitations of this research include the lack of post-natal fol-
low up measurements as well as the inability to independently
analyze the effects of opiates and nicotine on thalamic diameter.
This study would best be performed longitudinally in the future,
with smoking status incorporated as a controlled parameter, track-
ing changes in the thalamus diameter at birth and into childhood.
Also, as previously stated, determining the exact amount of opiate
and other illicit drug use during pregnancy in this cohort is intrin-
sically difficult to identify. Therefore, confounding factors such as
the effect of other substances potentially used during pregnancy
must be considered.
CONCLUSION
Opiate-exposure (primarily methadone) is associated with a sig-
nificant increase in thalamic diameter when compared to controls.
This could potentially be attributed to regional differences in opi-
oid and serotonin receptor densities, an alteration in monoamine
neurotransmitter systems, and an enhancement of the normal
growth increase that occurs in the thalamus during mid-gestation.
Pre-natal nicotine exposure also appears to increase the size of the
thalamus, though the effects are difficult to separate from that of
the opiates. None of the other growth parameters measured dur-
ing the FAS between 18 and 22 weeks were significantly different
to controls.
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